NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective countermeasures.
NV-387’s host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola. The company emphasized that its platform technology, based on TheraCour nanomedicine, enables rapid adaptation to emerging viral threats.
The Bundibugyo strain of Ebola, first identified in Uganda in 2007, has caused sporadic outbreaks with high mortality rates. The current outbreak in Africa is expanding, and the lack of specific medical countermeasures highlights the importance of broad-spectrum antivirals like NV-387. The company’s approach targets host cell mechanisms rather than viral proteins, potentially reducing the risk of resistance and broadening applicability across different viruses.
NanoViricides’ lead candidate NV-387 is also being developed for respiratory syncytial virus (RSV), COVID-19, influenza, and other respiratory infections, as well as mpox/smallpox and measles. The company has a worldwide exclusive perpetual license to TheraCour technology for several human viral diseases, including Ebola/Marburg viruses. The company’s business model relies on licensing technology from TheraCour Pharma Inc., with a focus on advancing NV-387 into Phase II human clinical trials.
The announcement comes as global health authorities seek to contain the Bundibugyo outbreak. The World Health Organization has reported cases in multiple countries, and the need for treatments that can be deployed quickly in resource-limited settings is paramount. NV-387’s oral formulation could simplify logistics compared to injectable therapies, potentially improving access in remote areas.
While the company is optimistic about NV-387’s potential, it acknowledges the inherent risks in drug development. As with any pharmaceutical candidate, there can be no assurance of sufficient effectiveness or safety for human clinical development. The path to approval is lengthy and requires substantial capital. Nevertheless, the company’s ongoing preparations for a Phase II mpox trial in the DRC could provide a pathway for evaluating the drug against Ebola in the region.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC.